Document is current
Any future updates will be listed below
-
Authors
Silverstein, Brian H.
Kolbman, Nicholas
Nelson, Amanda
Liu, Tiecheng
Guzzo, Peter https://orcid.org/0009-0007-4773-8052
Gilligan, Jim
Lee, UnCheol https://orcid.org/0000-0001-7858-0381
Mashour, George A.
Vanini, Giancarlo
Pal, Dinesh https://orcid.org/0000-0003-1239-5057
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01GM111293, R01GM121919, GM111293)
Tryp Therapeutics, Kelowna, British Columbia, Canada University of Michigan Department of Anesthesiology
- License Information
-
More Information
Article History
Received: 12 March 2024
Revised: 23 January 2025
Accepted: 11 March 2025
First Online: 25 March 2025
Competing interests
: Jim Gilligan, Ph.D. is President & Chief Scientific Officer at Tryp Therapeutics. Peter Guzzo, PhD is Consulting VP, Drug Development at Tryp Therapeutics.
: All experiments were approved by the Institutional Animal Care and Use Committee at the University of Michigan, Ann Arbor, and were conducted in compliance with the Guide for the Care and Use of Laboratory Animals (Ed 8, National Academies Press) and ARRIVE Guidelines.
